Literature DB >> 30128023

MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.

Chunhui Lang1,2, Miao Xu1, Ziyi Zhao3, Jinyao Chen1, Lishi Zhang1.   

Abstract

MicroRNA-96 (miR-96) is transcriptionally associated with the induction of chemoresistance following chemotherapy by targeting to FOXO1 mRNA at one of two predicted binding sites in its 3'-untranslated region sequence. The upregulation of miR-96 is associated with a high risk of chemoresistance. Nevertheless, the mechanism by which miR-96 is upregulated remains largely undefined. In the present study, the gastric cancer SGC7901 cell line was treated with different doses of the chemotherapeutic agents cisplatin and doxorubicin. miR-96 expression was analyzed by reverse transcription-quantitative polymerase chain reaction at different time points. Western blot and chromatin immunoprecipitation were performed to analyze the expression levels of the target gene. The effects of miR-96 on chemosensitivity were assessed by a carboxyfluorescein succinimidyl ester/propidium iodide labeling assay, and its effects on proliferation were assessed by Cell Counting Kit-8 or EdU staining assays. The results demonstrated that treatment with a low dose of either chemotherapeutic agent induced miR-96 expression. Upregulation of miR-96 caused the post-transcriptional repression of FOXO1 expression. Decreases in FOXO1 protein levels led to a decrease in the transcriptional activity of the cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21) promoter region, and thus the expression of p21 was downregulated in a tumor protein p53-independent manner. As a result, induction of miR-96 expression caused chemoresistance and promoted proliferation in SGC7901 cells. Taken together, the results of the present study revealed that treatment with cisplatin or doxorubicin could induce expression of miR-96 at certain doses. Upregulation of miR-96 is partially associated with chemoresistance and miR-96 can also promote cell proliferation by repressing p21.

Entities:  

Keywords:  SGC7901; cell death; chemosensitivity; cisplatin; doxorubicin; forkhead box protein O1; microRNA-96; proliferation

Year:  2018        PMID: 30128023      PMCID: PMC6096113          DOI: 10.3892/ol.2018.9122

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells.

Authors:  Rong-Xin Chen; Yun-Hong Xia; Tong-Chun Xue; Sheng-Long Ye
Journal:  Mol Med Rep       Date:  2011-12-06       Impact factor: 2.952

3.  Nodal dissection for patients with gastric cancer: a randomised controlled trial.

Authors:  Chew-Wun Wu; Chao A Hsiung; Su-Shun Lo; Mao-Chin Hsieh; Jen-Hao Chen; Anna Fen-Yau Li; Wing-Yiu Lui; Jacqueline Whang-Peng
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

Review 4.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

Authors:  Witold Filipowicz; Suvendra N Bhattacharyya; Nahum Sonenberg
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

Review 5.  Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology.

Authors:  Elizabeth C Smyth; David Cunningham
Journal:  Nat Rev Clin Oncol       Date:  2013-01-08       Impact factor: 66.675

6.  Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.

Authors:  A E Dassen; V E P P Lemmens; L V van de Poll-Franse; G J Creemers; S J Brenninkmeijer; D J Lips; A A M Vd Wurff; K Bosscha; J W W Coebergh
Journal:  Eur J Cancer       Date:  2010-03-08       Impact factor: 9.162

Review 7.  Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Authors:  Koji Oba; Xavier Paoletti; Yung-Jue Bang; Harry Bleiberg; Tomasz Burzykowski; Nozomu Fuse; Stefan Michiels; Satoshi Morita; Yasuo Ohashi; Jean-Pierre Pignon; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Kohei Shitara; Akira Tsuburaya; Eric Van Cutsem; Marc Buyse
Journal:  Eur J Cancer       Date:  2013-01-24       Impact factor: 9.162

8.  Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1.

Authors:  Benedikta S Haflidadóttir; Olivia Larne; Myriam Martin; Margareta Persson; Anders Edsjö; Anders Bjartell; Yvonne Ceder
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

9.  miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.

Authors:  Yeting Hong; Hongwei Liang; Yanbo Wang; Weijie Zhang; Yong Zhou; Song'an Chen; Mengchao Yu; Sufang Cui; Minghui Liu; Nan Wang; Chao Ye; Chihao Zhao; Yanqing Liu; Qian Fan; Chen-Yu Zhang; Jianfeng Sang; Ke Zen; Xi Chen
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

10.  Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer.

Authors:  Ziyu Wu; Kun Liu; Yunyan Wang; Zongyuan Xu; Junsong Meng; Shuo Gu
Journal:  Cancer Cell Int       Date:  2015-11-14       Impact factor: 5.722

View more
  7 in total

Review 1.  The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.

Authors:  Zahra Torki; Davood Ghavi; Solmaz Hashemi; Yazdan Rahmati; Dara Rahmanpour; Majid Pornour; Mohammad Reza Alivand
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-12       Impact factor: 3.333

Review 2.  MicroRNA-96: A therapeutic and diagnostic tumor marker.

Authors:  Hamid Reza Rahimi; Majid Mojarrad; Meysam Moghbeli
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

Review 3.  Clinical crosstalk between microRNAs and gastric cancer (Review).

Authors:  Jing Ouyang; Zhizhong Xie; Xiaoyong Lei; Guotao Tang; Runliang Gan; Xiaoyan Yang
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

Review 4.  Exploring the role of non-coding RNAs in autophagy.

Authors:  Soudeh Ghafouri-Fard; Hamed Shoorei; Mahdi Mohaqiq; Jamal Majidpoor; Mohammad Amin Moosavi; Mohammad Taheri
Journal:  Autophagy       Date:  2021-02-18       Impact factor: 13.391

5.  Knockdown of miR-183 Enhances the Cisplatin-Induced Apoptosis in Esophageal Cancer Through Increase of FOXO1 Expression.

Authors:  Hao Chen; Bin Zheng; Songtao Xue; Chun Chen
Journal:  Onco Targets Ther       Date:  2020-08-24       Impact factor: 4.147

6.  Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.

Authors:  Dan Wang; Li Yang; Weina Yu; Qian Wu; Jingyao Lian; Feng Li; Shasha Liu; Aitian Li; Zhiang He; Jinbo Liu; Zhenqiang Sun; Weitang Yuan; Yi Zhang
Journal:  J Immunother Cancer       Date:  2019-08-08       Impact factor: 13.751

Review 7.  Research Progress in microRNA-Based Therapy for Gastric Cancer.

Authors:  Xu Zhao; Gao-Feng Hu; Yan-Fen Shi; Wei Xu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.